Status:
COMPLETED
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
Lead Sponsor:
Eisai Co., Ltd.
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
45-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
Eligibility Criteria
Inclusion
- 45 - 80 years old (at time of informed consent)
- Male or female (females of childbearing potential must be contracepted)
- Confirmed acute coronary syndrome
Exclusion
- Unwilling or unable to provide informed consent
- History of acquired or congenital bleeding disorder, coagulopathy, or platelet disorder
- Recent trauma or major surgery
- Evidence of active pathological bleeding at screening or history of gastrointestinal or genitourinary bleeding with unknown cause within 24 weeks prior to screening
- History of intracranial bleeding or history of hemorrhagic retinopathy
- History of New York Heart Association (NYHA) class III or IV congestive heart failure
- Pregnant or lactating women
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00619164
Start Date
November 1 2007
Last Update
May 13 2013
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Toyoake, Aichi-ken, Japan
2
Fukuoka, Fukuoka, Japan
3
Kasuga, Fukuoka, Japan
4
Kitakyushu, Fukuoka, Japan